Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2026-01-07 00:00:00 ET · period of report 2026-01-05 · accession 0001193125-26-006288 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-07 | 2026-01-05 | NTLA | Cohen Fred E | Dir | P - Purchase | $9.35 | +150.0K | 207.5K | +261% | +$1.40M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-05 | P | A | 150,000 | $9.35 | 207,453 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price. |